TY - JOUR T1 - Mass administration of azithromycin reduces childhood mortality in Niger JF - Archives of disease in childhood - Education & practice edition JO - Arch Dis Child Educ Pract Ed SP - 320 LP - 320 DO - 10.1136/archdischild-2020-319718 VL - 106 IS - 5 AU - Sarah Murphy AU - Mehreen S Datoo Y1 - 2021/10/01 UR - http://ep.bmj.com/content/106/5/320.abstract N2 - Review of: Keenan JD, Arzika AM, Maliki R, et al. Longer-term assessment of azithromycin for reducing childhood mortality in Africa. N Engl J Med. 2019;380:2207–14. Study design: This study, MORDOR II, is a continuation study of the MORDOR I trial. In MORDOR I, participants were randomised to receive either azithromycin or placebo biannually for 2 years. MORDOR II is an observational study specifically investigating the effect of subsequent administration of azithromycin to both the original placebo and azithromycin treatment arms of the trial in Niger for a further year. Therefore, participants were followed up for a total of 3 years. Participants and observers in this continuation study remained blinded to their original treatment arm from MORDOR I. Patients: Infants and children (1–59 months of age) originally enrolled in MORDOR I in Niger, who had previously been randomised to receive either azithromycin or … ER -